A 32-year-old male with CML, who had undergone BMT, developed fever of unknown origin. This did not respond to antibiotics and he was given Abelcet empirically. However, shortly after the Abelcet infusion was started, he developed pulmonary symptoms with dyspnoea, cough and a reduced oxygen saturation. Abelcet was discontinued and he was given oxygen, steroids and terbutalin sulph. After 4 h, the infusion of Abelcet was reinstituted, but again he developed pulmonary obstruction and a lowered PO 2 . Abelcet was discontinued after a total of less than 1 mg/kg had been given. The following morning, chest Xray revealed interstitial pulmonary infiltrates, which disappeared after 4 days.
Due to side-effects of Abelcet, steroids were given to six patients, antihistamines to three, oxygen to three and paracetamol to one. Abelcet was replaced by AmBisome (Nexstar, San Dimas, CA, USA) in seven patients due to side-effects such as chills (three), severe vomiting (two), fever (two), erythema (two), reduced PO 2 (two) and haemolysis (one). All side-effects disappeared during AmBisome treatment. Two patients, in addition, had increased serum creatinine values, 216 and 165 mol/l, respectively, during Abelcet treatment. Serum creatinine decreased to 168 and 103, respectively, 1 week after the switch in therapy. AmBisome was given for a median of 10 (range 3-29) days. Abelcet was switched to ketoconazole in two patients, due to haemorrhagic erythema and severe vomiting, respectively. Side-effects disappeared and ketoconazole was continued for 7 and 10 days, respectively.
A 72-year-old female with B cell lymphoma with suspected fungal pneumonia experienced severe vomiting during Abelcet infusion (4 mg/kg/day). After 5 days of treatment, serum creatinine increased from 90 to 345 mol/l and bilirubin from 18 to 43 mol/l. She was switched to itraconazole, 200 mg/kg/day, given for 10 days. After 1 week, serum creatinine decreased to 150 mol/l and the bilirubin normalised at 21 mol/l. Two further patients who tolerated 11 and 15 days of Abelcet without adverse events, were switched to itraconazole and fluconazole, respectively.
In four patients, we attempted to give Abelcet at a lower dose, from 1 to 2.5 mg/kg/day, with antihistamine and corticosteroid premedication. In three of these patients, it was discontinued due to side-effects. However, a 24-year-old woman with AML who had had a BMT 10 months earlier, tolerated Abelcet well for 15 days' treatment of a suspected pulmonary infection. Due to toxic side-effects, treatment with Abelcet could only be continued for between 10 and 19 days in 5/19 (26%) of the patients.
All patients were very ill and most had been treated with a number of potentially toxic drugs. However, in all instances the side-effects had a direct and obvious correlation with infusion of Abelcet.
In our experience Abelcet is far more toxic than AmBisome, which does not necessitate routine use of antihistamines or steroids and has few, mostly tolerable, side-effects. 2 AmBisome was discontinued in only 3% (6/187) of patients, due to toxicity, compared to 74% with Abelcet (P Ͻ 0.001).
2 Of these patients, 89 were bone marrow transplant recipients and 98 were organ transplant recipients; all were treated with CsA. Median age was 36 years (0.5-72). AmBisome was given for a median of 11 days (range 1-112) with a maximum daily dose of 1.49 ± 0.7 mg/kg (mean ± s.d.). Details have been previously published. 6 It should be noted that AmBisome was used at a much lower dose in most patients. Whether Abelcet should be started at a lower dose, giving prophylaxis with antihistamines and steroids, requires exploration in further trials. Furthermore, it is not known which preparation of amphotericin B is most effective. Therefore, prospective comparative trials of the new formulations of amphotericin B are warranted, not only to compare sideeffects, but also cost-effectiveness. 5 We do not know the reason for the severe side-effects seen in our patients in contrast to two previous reports. 3, 4 Perhaps Scandinavian people are more sensitive to Abelcet than are those from the UK and the USA, or our patients received a more toxic batch. Another possibility may be that we compared Abelcet with our previous experience with AmBisome and found toxicity unacceptable. In the USA, toxicity by Abelcet may have been compared to that seen with conventional amphotericin B. 4 To clarify these issues, we encourage other colleagues to report their experiences with Abelcet.
Use of the recommended dose of 5 mg/kg/day, and also lower doses in a few patients, resulted in a high rate of toxicity. We also wish to alert our colleagues to the potential for severe side-effects with Abelcet in some patients not reported previously. 
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